American Trust Increases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

American Trust increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 5.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,864 shares of the medical equipment provider’s stock after buying an additional 238 shares during the period. American Trust’s holdings in Hologic were worth $314,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Hologic by 5.1% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock valued at $2,569,000 after buying an additional 1,631 shares in the last quarter. LSV Asset Management lifted its holdings in Hologic by 307.5% in the 1st quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock valued at $2,911,000 after purchasing an additional 28,600 shares in the last quarter. Raymond James Trust N.A. lifted its holdings in Hologic by 7.4% in the 1st quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock valued at $528,000 after purchasing an additional 476 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Hologic by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock valued at $177,098,000 after purchasing an additional 106,315 shares in the last quarter. Finally, Aviva PLC lifted its holdings in Hologic by 0.7% in the 1st quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock valued at $5,803,000 after purchasing an additional 513 shares in the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Hologic Stock Down 1.6 %

Shares of NASDAQ:HOLX opened at $77.07 on Friday. The business has a 50-day moving average price of $81.04 and a 200 day moving average price of $74.00. The company has a current ratio of 4.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $19.00 billion, a price-to-earnings ratio of 19.66, a PEG ratio of 1.40 and a beta of 1.01. Hologic, Inc. has a 12-month low of $59.78 and a 12-month high of $86.65.

Hologic (NASDAQ:HOLX – Get Rating) last released its earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.17. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 25.12% and a net margin of 22.17%. Hologic’s revenue was down 27.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.17 EPS. Sell-side analysts expect that Hologic, Inc. will post 3.74 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on HOLX. Citigroup raised their price objective on Hologic from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Thursday, February 2nd. JPMorgan Chase & Co. raised their target price on Hologic from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Thursday, February 2nd. Cowen raised their target price on Hologic from $86.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, February 2nd. StockNews.com initiated coverage on Hologic in a research note on Thursday. They issued a “buy” rating for the company. Finally, Morgan Stanley raised their target price on Hologic from $74.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Friday, February 3rd. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $84.08.

Insider Buying and Selling at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 9,128 shares of Hologic stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $85.28, for a total value of $778,435.84. Following the completion of the transaction, the insider now directly owns 14,298 shares of the company’s stock, valued at approximately $1,219,333.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.66% of the stock is currently owned by corporate insiders.

Hologic Company Profile

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.